Regentis Biomaterials is a global biomaterials company dedicated to developing groundbreaking tissue repair solutions that restore the health and quality of life of patients.
The company’s current efforts are focused on orthopedic treatments using degradable hydrogel implants to regenerate damaged or diseased tissue. Gelrin is the regenerative hydrogel platform for all product development.
The company’s first commercial product is GelrinCTM, a cell-free, off-the-shelf hydrogel implant for the treatment of painful injuries to articular knee cartilage. This cost-effective treatment offers orthopedic surgeons a simple to perform procedure while providing patients with sustained pain relief and function improvement.